Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer.

Autor: Sfakianaki M; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece., Papadaki C; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece., Tzardi M; Department of Pathology, University General Hospital of Heraklion, Iraklio, Greece., Trypaki M; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece., Alam S; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece., Lagoudaki ED; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece., Messaritakis I; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece., Zoras O; Department of Surgical Oncology, University General Hospital of Heraklion, Iraklio, Greece., Mavroudis D; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.; Department of Medical Oncology, University General Hospital of Heraklion, Iraklio, Greece., Georgoulias V; School of Medicine, University of Crete, Heraklion, Greece., Souglakos J; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.; Department of Medical Oncology, University General Hospital of Heraklion, Iraklio, Greece.
Jazyk: angličtina
Zdroj: Cancer research and treatment [Cancer Res Treat] 2019 Oct; Vol. 51 (4), pp. 1518-1526. Date of Electronic Publication: 2019 Mar 20.
DOI: 10.4143/crt.2019.008
Abstrakt: Purpose: The purpose of this study was to investigate the prognostic significance of liver kinase b1 (LKB1) loss in patients with operable colon cancer (CC).
Materials and Methods: Two hundred sixty-two specimens from consecutive patients with stage III or high-risk stage II CC, who underwent surgical resection with curative intent and received adjuvant chemotherapy with fluoropyrimidine and oxaliplatin, were analyzed for LKB1 protein expression loss, by immunohistochemistry as well as for KRAS exon 2 and BRAFV600E mutations by Sanger sequencing and TS, ERCC1, MYC, and NEDD9 mRNA expression by real-time quantitative reverse transcription polymerase chain reaction.
Results: LKB1 expression loss was observed in 117 patients (44.7%) patients and correlated with right-sided located primaries (p=0.032), and pericolic lymph nodes involvement (p=0.003), BRAFV600E mutations (p=0.024), and TS mRNA expression (p=0.041). Patients with LKB1 expression loss experienced significantly lower disease-free survival (DFS) (hazard ratio [HR], 1.287; 95% confidence interval [CI], 1.093 to 1.654; p=0.021) and overall survival (OS) (HR, 1.541; 95% CI, 1.197 to 1.932; p=0.002), compared to patients with LKB1 expressing expressing tumors. Multivariate analysis revealed LKB1 expression loss as independent prognostic factor for both decreased DFS (HR, 1.217; 95% CI, 1.074 to 1.812; p=0.034) and decreased OS (HR, 1.467; 95% CI, 1.226 to 2.122; p=0.019).
Conclusion: Loss of tumoral LKB1 protein expression, constitutes an adverse prognostic factor in patients with operable CC.
Databáze: MEDLINE
Externí odkaz: